OXFORD BIOTHERAPEUTICS LTD has a total of 487 patent applications. It increased the IP activity by 22.0%. Its first patent ever was published in 2007. It filed its patents most often in United Kingdom, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are VANCOUVER BIOTECH LTD, NEOGENIX ONCOLOGY INC and IMMULOGIC PHARMA CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 308 | |
#2 | EPO (European Patent Office) | 24 | |
#3 | WIPO (World Intellectual Property Organization) | 19 | |
#4 | United States | 17 | |
#5 | Australia | 11 | |
#6 | China | 8 | |
#7 | Republic of Korea | 8 | |
#8 | Brazil | 7 | |
#9 | Canada | 7 | |
#10 | Singapore | 7 | |
#11 | Israel | 6 | |
#12 | Japan | 5 | |
#13 | Mexico | 5 | |
#14 | New Zealand | 5 | |
#15 | Chile | 4 | |
#16 | EAPO (Eurasian Patent Organization) | 4 | |
#17 | Hungary | 4 | |
#18 | Costa Rica | 3 | |
#19 | Dominican Republic | 3 | |
#20 | Hong Kong | 3 | |
#21 | Peru | 3 | |
#22 | South Africa | 3 | |
#23 | Argentina | 2 | |
#24 | Colombia | 2 | |
#25 | Ecuador | 2 | |
#26 | Morocco | 2 | |
#27 | Montenegro | 2 | |
#28 | Serbia | 2 | |
#29 | Slovenia | 2 | |
#30 | Tunisia | 2 | |
#31 | Taiwan | 2 | |
#32 | African Regional Industrial Property Organization | 1 | |
#33 | Guatemala | 1 | |
#34 | Nicaragua | 1 | |
#35 | Philippines | 1 | |
#36 | Ukraine | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Machines | |
#5 | Electrical machinery and energy | |
#6 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Rohlff Christian | 90 |
#2 | Terrett Jonathan Alexander | 86 |
#3 | Ackroyd James Edward | 32 |
#4 | Stamps Alasdair | 23 |
#5 | Huang Haichun | 10 |
#6 | Meaddough Erika | 10 |
#7 | Pan Chin | 10 |
#8 | Bisht Arnima | 9 |
#9 | Hannum Chuck | 8 |
#10 | Deban Livija | 8 |
Publication | Filing date | Title |
---|---|---|
GB202016953D0 | Therapeutic and diagnostic target | |
GB202016852D0 | Therapeutic and diagnostic target | |
GB202016867D0 | Therapeutic and diagnostic target | |
GB202016869D0 | Therapeutic and diagnostic target | |
GB202016434D0 | Therapeutic and diagnostic target | |
GB202016467D0 | Therapeutic and diagnostic target | |
WO2021001653A1 | Antibodies and methods of use | |
GB202004404D0 | Chimeric antigen receptors | |
GB202001261D0 | Chimeric antigen receptors | |
GB201910130D0 | Therapeutic and diagnostic target | |
GB201908239D0 | Chimeric antigen receptors | |
GB201900401D0 | Therapeutic and diagnostic target | |
GB201900408D0 | Therapeutic and diagnostic target | |
GB201900423D0 | Therapeutic and diagnostic target | |
GB201900393D0 | Therapeutic and diagnostics target | |
GB201900418D0 | Therapeutic and diagnostic target | |
GB201900411D0 | Therapeutic and diagnostic target | |
BR112020008438A2 | antibodies and methods of use | |
GB201812388D0 | Therapeutic and diagnostic target | |
GB201804219D0 | Therapeutic and diagnostic target |